Related Experiment Video
Updated: Jan 23, 2026

Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure
Published on: August 28, 2009
Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1
Leilei Zhang1, Jie Zhang1, Zhiwei Ye1
1Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina.
Abstract:
ME-344 is a second-generation isoflavone with unusual cytotoxic properties that is in clinical testing in cancer. To identify targets that contribute to its anticancer activity and therapeutic index, we used lung cancer cell lines that are naturally sensitive or resistant to ME-344. Drug-induced apoptosis was linked with enhanced levels of reactive oxygen species and this initiated a nuclear erythroid factor 2-like 2 signaling response, downstream of which, heme oxygenase 1 (HO-1) was also found to be time-dependently inhibited by ME-344. ME-344 specifically bound to, and altered, HO-1 structure and increased HO-1 translocation from the rough endoplasmic reticulum to mitochondria, but only in drug-sensitive cells. These effects did not occur in either drug-resistant or primary lung fibroblasts with lower HO-1 basal levels. HO-1 was confirmed as a drug target by using surface plasmon resonance technology and through interaction with a clickable ME-344 compound (M2F) and subsequent proteomic analyses, showing direct binding of ME-344 with HO-1. Proteomic analysis showed that clusters of mitochondrial proteins, including voltage-dependent anion-selective channels, were also impacted by ME-344. Human lung cancer biopsies expressed higher levels of Nrf2 and HO-1 compared with normal tissues. Overall, our data show that ME-344 inhibits HO-1 and impacts its mitochondrial translocation. Other mitochondrial proteins are also affected, resulting in interference in tumor cell redox homeostasis and mitochondrial function. These factors contribute to a beneficial therapeutic index and support continued clinical development of ME-344. SIGNIFICANCE: A novel cytotoxic isoflavone is shown to inhibit heme oxygenase, a desirable yet elusive target that disrupts redox homeostasis causing cell death.
Insights
The anticancer drug ME-344 targets heme oxygenase 1 (HO-1), disrupting cancer cell redox balance and mitochondrial function. This mechanism contributes to its effectiveness and supports its clinical development for cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- ME-344 is a novel isoflavone derivative with demonstrated cytotoxic properties.
- Its mechanism of action and specific molecular targets in cancer, particularly lung cancer, require elucidation.
- Understanding ME-344's interaction with cellular pathways is crucial for optimizing its therapeutic potential.
Purpose of the Study:
- To identify the molecular targets of ME-344 that mediate its anticancer activity.
- To investigate the role of heme oxygenase 1 (HO-1) in ME-344's cytotoxic effects.
- To explore the impact of ME-344 on cellular redox homeostasis and mitochondrial function.
Main Methods:
- Utilized drug-sensitive and drug-resistant lung cancer cell lines.
- Assessed drug-induced apoptosis, reactive oxygen species (ROS) levels, and nuclear erythroid factor 2-like 2 (Nrf2) signaling.
- Employed surface plasmon resonance, clickable chemical probes, and proteomic analyses to confirm ME-344 binding to HO-1.
- Examined ME-344's effect on HO-1 translocation and mitochondrial protein expression.
Main Results:
- ME-344 induced apoptosis, increased ROS, and activated Nrf2 signaling in sensitive cells.
- ME-344 directly inhibited HO-1 activity and altered its structure, promoting translocation to mitochondria in sensitive cells.
- HO-1 was confirmed as a direct binding target of ME-344.
- ME-344 affected mitochondrial proteins, including voltage-dependent anion-selective channels, impacting cellular redox and mitochondrial function.
- Elevated Nrf2 and HO-1 levels were observed in human lung cancer biopsies compared to normal tissues.
Conclusions:
- ME-344 exerts its anticancer effects by inhibiting HO-1 and disrupting its mitochondrial localization.
- The drug interferes with tumor cell redox homeostasis and mitochondrial function, contributing to its therapeutic index.
- These findings validate HO-1 as a target for ME-344 and support its continued clinical investigation.
Related Concept Videos
Balancing Redox Equations
Redox Reactions
Redox Reactions
What is Homeostasis?
pH Homeostasis
Respiratory...
Animal Mitochondrial Genetics

